Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 24   

Articles published

OCRX 5.24 +0.13 (2.54%)
price chart
Ocera Therapeutics Finally Ready To Reward Investors
The offering was priced at $6 per share and netted the company 25.2 million. Following the announcement the stock gapped down to $6.
Ocera Therapeutics to Present at 13th Annual BIO Investor Forum
PALO ALTO, Calif., Sept. 29, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be ...
Related articles »  
Ocera Therapeutics Reaches New 1-Year Low at $5.26 (OCRX)
Ocera Therapeutics logo Ocera Therapeutics (NASDAQ:OCRX)'s share price hit a new 52-week low during trading on Monday , AnalystRatings.
Eye Catching Stocks: Ocera Therapeutics, Inc. (NASDAQ:OCRX), The Procter ...
Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that Steven P. James has been appointed to the Company's Board of Directors.
Ocera Therapeutics To Present At BIO Investor Forum; Webcast At 6:00 PM ET
(RTTNews.com) - Ocera Therapeutics, Inc.( OCRX ) will present at the 13th Annual BIO Investor Forum being held at the Palace Hotel in San Francisco, California.
Leading Small-Cap Stars Health Care Stock for October 22 Morning Session is ...
Ocera Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.
Related articles »  
Leading Small-Cap Stars Health Care Stock for October 17 Morning Session is ...
Ocera Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.
Related articles »  
Leading Health Care Stock for Small-Cap Stars is Tranzyme Inc (OCRX) for ...
Ocera Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.
Biotech Decliners: Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR ...
On September 17, 2014, the Board of Directors of Ocera Therapeutics, Inc. (NASDAQ:OCRX) elected Steven P. James as a director, to serve until the annual meeting of stockholders in 2015 and until his successor is duly elected and qualified or until his ...
Leading Small-Cap Stars Health Care Stock for September 25 Morning Session ...
Ocera Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need.
Related articles »